

A DECLARATION OF JOINT WORKING

BETWEEN

AstraZeneca UK Ltd

AND

The Royal Liverpool and Broadgreen University Hospital NHS Trust (The Royal Liverpool Hospital)

The Royal Liverpool and Broadgreen University Hospital NHS Trust (The Royal Liverpool Hospital) and AstraZeneca are engaged in a Joint Working project called 'Supporting and optimising treatment of Asthma patients in a Severe Asthma setting by objectively measuring adherence through the introduction of Turbu+, a digital intervention'.

This project will run from July 2020 to July 2021 and both parties have contributed resources for this initiative.

The Joint Working Project will utilise a digital intervention (Turbu+) for asthma patients already prescribed Symbicort Turbohaler referred to the Severe Asthma Service at The Royal Liverpool Hospital Severe Asthma Centre.

Phase 1: (4 weeks for each enrolled patient)

This intervention will objectively measure adherence in inhaled maintenance therapy with Symbicort Turbohaler in patients, leading to three possible outcomes:

1. Identify patients who are non-adherent to their inhaled therapy despite this intervention and for whom the initiation of biologic therapies would be inappropriate.
2. Improve asthma outcomes in patients previously non-adherent with no further interventions necessary.
3. Identify patients whose asthma control remains sub-optimal despite good adherence whom may subsequently be eligible for biologic therapy.

Phase 2: Continued use of the Turbu+ for up to 12 months to continue to monitor adherence for all patients entering phase 2, if the patient continues to be treated in the severe asthma setting.

Treatment decisions are entirely the control of The Royal Liverpool Hospital Severe Asthma Centre in line with their protocol.